Anti-Human PCSK9 Recombinant Antibody (SAA2543) (HV275033)

Name: Anti-Human PCSK9 Recombinant Antibody (SAA2543)
Brand: abinScience
SKU: HV275033
Price: 126 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

20ug
50ug
100ug
1mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue

HV275033

Reactivité des espèces

Human

Applications

ELISA

Clonalité

Monoclonal

Isotype

scFv-His

ID de clone

SAA2543

Cible

EC:3.4.21.-, NARC-1, NARC1, Neural apoptosis-regulated convertase 1, PC9, PCSK9, Proprotein convertase 9, Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9

Niveau d'endotoxines

< 10 EU/mg

Pureté

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Numéro d'accès

Q8NBP7

Forme

Liquid

Tampon de stockage

0.01M PBS pH 7.4.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
ELISA	1:2000-1:20000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Contexte

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha).

1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658

2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796

3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702

4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458

5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827

6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751

Note

For research use only

Images